{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:34:51Z","timestamp":1790670891673,"version":"4.1.0"},"reference-count":216,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.3960\/jslrt.17023","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T22:15:28Z","timestamp":1514326528000},"page":"120-142","source":"Crossref","is-referenced-by-count":100,"title":["Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects"],"prefix":"10.3960","volume":"57","author":[{"given":"Naoko","family":"Tsuyama","sequence":"first","affiliation":[{"name":"Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Sakata","sequence":"additional","affiliation":[{"name":"Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research"},{"name":"Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Stein H, Mason D Y , Gerdes J, O\u2019Connor N, Wainscoat J, <i>et al<\/i>.: The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66: 848-858, 1985"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Stansfeld A G , Diebold J, Noel H, Kapanci Y, Rilke F, <i>et al<\/i>.: Updated Kiel classification for lymphomas. Lancet 1: 292-293, 1988","DOI":"10.1016\/S0140-6736(88)90367-4"},{"key":"3","unstructured":"3 Falini B, Pileri, S, Pizzolo G, Durkop H, Flenghi L, <i>et al<\/i>.: CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85: 1-14, 1995"},{"key":"4","unstructured":"4 Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, <i>et al<\/i>.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392, 1994"},{"key":"5","unstructured":"5 Swerdlow S H, Campo E, Harris N L, Jaffe E S, Pileri S A, Stein H, Thiele J, Vardiman J W: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition, 2008"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Project T N -H s L C: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 89: 3909-3918, 1997","DOI":"10.1182\/blood.V89.11.3909"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Vose J, Armitage J, Weisenburger D, International T C L P: International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124-4130, 2008","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"8","unstructured":"8 Lamant L, Pileri S, Sabattini E, Brugieres L, Jaffe E S, <i>et al<\/i>.: Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Haematologica 95: 449-455, 2010"},{"key":"9","unstructured":"9 Savage K J, Harris N L, Vose J M, Ullrich F, Jaffe E S, <i>et al<\/i>.: ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111: 5496-5504, 2008"},{"key":"10","unstructured":"10 Falini B, Pileri S, Zinzani P L, Carbone A, Zagonel V, <i>et al<\/i>.: ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93: 2697-2706, 1999"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Gascoyne R D, Aoun P, Wu D, Chhanabhai M, Skinnider B F, <i>et al<\/i>.: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93: 3913-3921, 1999","DOI":"10.1182\/blood.V93.11.3913.411k22_3913_3921"},{"key":"12","unstructured":"12 Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, <i>et al<\/i>.: Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype. Blood 96: 2993-3000, 2000"},{"key":"13","unstructured":"13 Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho A D, <i>et al<\/i>.: Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116: 3418-3425, 2010"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Sibon D, Fournier M, Briere J, Lamant L, Haioun C, <i>et al<\/i>.: Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials. J Clin Oncol 30: 3939-3946, 2012","DOI":"10.1200\/JCO.2012.42.2345"},{"key":"15","unstructured":"15 Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, <i>et al<\/i>.: ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91: 2076-2084, 1998"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 ten Berge R L, de Bruin P C, Oudejans J J, Ossenkoppele G J, van der Valk P, <i>et al<\/i>.: ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 43: 462-469, 2003","DOI":"10.1046\/j.1365-2559.2003.01726.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ellin F, Landstrom J, Jerkeman M, Relander T: Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124: 1570-1577, 2014","DOI":"10.1182\/blood-2014-04-573089"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Eyre T A, Khan D, Hall G W, Collins G P: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. Eur J Haematol 93: 455-468, 2014","DOI":"10.1111\/ejh.12360"},{"key":"19","unstructured":"19 Brugieres L, Deley M C, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe M J, <i>et al<\/i>.: CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92: 3591-3598, 1998"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Fraga M, Brousset P, Schlaifer D, Payen C, Robert A, <i>et al<\/i>.: Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 103: 82-89, 1995","DOI":"10.1093\/ajcp\/103.1.82"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Nomura M, Narita Y, Miyakita Y, Ohno M, Fukushima S, <i>et al<\/i>.: Clinical presentation of anaplastic large-cell lymphoma in the central nervous system. Mol Clin Oncol 1: 655-660, 2013","DOI":"10.3892\/mco.2013.110"},{"key":"22","unstructured":"22 Williams D, Mori T, Reiter A, Woessman W, Rosolen A, <i>et al<\/i>.: Central nervous system involvement in anaplastic large cell lymphoma in childhood: results from a multicentre European and Japanese study. Pediatr Blood Cancer 60: E118-121, 2013"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Hapgood G, Savage K J: The biology and management of systemic anaplastic large cell lymphoma. Blood 126: 17-25, 2015","DOI":"10.1182\/blood-2014-10-567461"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Ellin F, Landstrom J, Jerkeman M, Relander T: Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood 126: 36-41, 2015","DOI":"10.1182\/blood-2014-12-616961"},{"key":"25","unstructured":"25 Bayle C, Charpentier A, Duchayne E, Manel A M, Pages M P, <i>et al<\/i>.: Leukaemic presentation of small cell variant anaplastic large cell lymphoma: report of four cases. Br J Haematol 104: 680-688, 1999"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Kinney M C, Collins R D, Greer J P, Whitlock J A, Sioutos N, <i>et al<\/i>.: A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. The American journal of surgical pathology 17: 859-868, 1993","DOI":"10.1097\/00000478-199309000-00001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Chan J K, Ng C S, Hui P K, Leung T W, Lo E S, <i>et al<\/i>.: Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types. Histopathology 15: 11-34, 1989","DOI":"10.1111\/j.1365-2559.1989.tb03038.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Chott A, Kaserer K, Augustin I, Vesely M, Heinz R, <i>et al<\/i>.: Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases. The American journal of surgical pathology 14: 439-448, 1990","DOI":"10.1097\/00000478-199005000-00003"},{"key":"29","unstructured":"29 Nakamura S, Shiota M, Nakagawa A, Yatabe Y, Kojima M, <i>et al<\/i>.: Anaplastic large cell lymphoma: a distinct molecular pathologic entity: a reappraisal with special reference to p80(NPM\/ALK) expression. The American journal of surgical pathology 21: 1420-1432, 1997"},{"key":"30","unstructured":"30 Pileri S A, Pulford K, Mori S, Mason D Y, Sabattini E, <i>et al<\/i>.: Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. <i>A<\/i>m J Pathol 150: 1207-1211, 1997"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri S A, <i>et al<\/i>.: ALK expression defines a distinct group of T\/null lymphomas (\u201cALK lymphomas\u201d) with a wide morphological spectrum. Am J Pathol 153: 875-886, 1998","DOI":"10.1016\/S0002-9440(10)65629-5"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Pileri S, Falini B, Delsol G, Stein H, Baglioni P, <i>et al<\/i>.: Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+\/Ki-1 + with a high content of reactive histiocytes). Histopathology 16: 383-391, 1990","DOI":"10.1111\/j.1365-2559.1990.tb01143.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Karl Lennert A C F: Histopathology of Non-Hodgkin\u2019s Lymphomas. Springer-Verlag Berlin Heidelberg, 1992","DOI":"10.1007\/978-3-642-97187-7"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Ott G, Bastian B C, Katzenberger T, Decoteau J F, Kalla J, <i>et al<\/i>.: A lymphohistiocytic variant of anaplastic large cell lymphoma with demonstration of the t(2;5)(p23;q35) chromosome translocation. Br J Haematol 100: 187-190, 1998","DOI":"10.1046\/j.1365-2141.1998.00531.x"},{"key":"35","unstructured":"35 Pileri S, Bocchia M, Baroni C D, Martelli M, Falini B, <i>et al<\/i>.: Anaplastic large cell lymphoma (CD30 +\/Ki-1+): results of a prospective clinico-pathological study of 69 cases. Br J Haematol 86: 513-523, 1994"},{"key":"36","unstructured":"36 Leoncini L, Del Vecchio M T, Kraft R, Megha T, Barbini P, <i>et al<\/i>.: Hodgkin\u2019s disease and CD30-positive anaplastic large cell lymphomas--a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study. Am J Pathol 137: 1047-1057, 1990"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Orscheschek K, Merz H, Hell J, Binder T, Bartels H, <i>et al<\/i>.: Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin\u2019s disease: indication of a common pathogenesis? Lancet 345: 87-90, 1995","DOI":"10.1016\/S0140-6736(95)90061-6"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 MacLennan K A, Bennett M H, Tu A, Hudson B V, Easterling M J, <i>et al<\/i>.: Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin\u2019s disease. A study of 1659 patients. Cancer 64: 1686-1693, 1989","DOI":"10.1002\/1097-0142(19891015)64:8<1686::AID-CNCR2820640822>3.0.CO;2-I"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Chan J K, Buchanan R, Fletcher C D: Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. The American journal of surgical pathology 14: 983-988, 1990","DOI":"10.1097\/00000478-199010000-00013"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, <i>et al<\/i>.: A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 89: 1483-1490, 1997","DOI":"10.1182\/blood.V89.5.1483.1483_1483_1490"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Swerdlow S H, Campo E, Pileri S A, Harris N L, Stein H, <i>et al<\/i>.: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375-2390, 2016","DOI":"10.1182\/blood-2016-01-643569"},{"key":"42","unstructured":"42 Pan Z, Hu S, Li M, Zhou Y, Kim Y S, <i>et al<\/i>.: ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature. The American journal of surgical pathology 41: 25-38, 2017"},{"key":"43","unstructured":"43 Sakamoto K, Nakasone H, Togashi Y, Sakata S, Tsuyama N, <i>et al<\/i>.: ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern. Int J Hematol 103: 399-408, 2016"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Horie R, Watanabe T: CD30: expression and function in health and disease. Seminars in immunology 10: 457-470, 1998","DOI":"10.1006\/smim.1998.0156"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Gedrich R W, Gilfillan M C, Duckett C S, Van Dongen J L, Thompson C B: CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 271: 12852-12858, 1996","DOI":"10.1074\/jbc.271.22.12852"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, <i>et al<\/i>.: Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells <i>in vitro<\/i> and <i>in vivo<\/i>. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. European journal of immunology 19: 157-162, 1989","DOI":"10.1002\/eji.1830190125"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Hansen H P, Kisseleva T, Kobarg J, Horn-Lohrens O, Havsteen, B, <i>et al<\/i>.: A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. International journal of cancer 63: 750-756, 1995","DOI":"10.1002\/ijc.2910630524"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Stein H, Gerdes J, Schwab U, Lemke H, Mason D Y, <i>et al<\/i>.: Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. International journal of cancer 30: 445-459, 1982","DOI":"10.1002\/ijc.2910300411"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Abbondanzo S L, Sato N, Straus S E, Jaffe E S: Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations. Am J Clin Pathol 93: 698-702, 1990","DOI":"10.1093\/ajcp\/93.5.698"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, <i>et al<\/i>.: JunB induced by constitutive CD30-extracellular signal-regulated kinase 1\/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 65: 7628-7634, 2005","DOI":"10.1158\/0008-5472.CAN-05-0925"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Hsu F Y, Johnston P B, Burke K A, Zhao Y: The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res 66: 9002-9008, 2006","DOI":"10.1158\/0008-5472.CAN-05-4101"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Staber P B, Vesely P, Haq N, Ott R G, Funato K, <i>et al<\/i>.: The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1\/2 and JunB translation via mTOR signaling. Blood 110: 3374-3383, 2007","DOI":"10.1182\/blood-2007-02-071258"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Duckett C S, Gedrich R W, Gilfillan M C, Thompson C B: Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Molecular and cellular biology 17: 1535-1542, 1997","DOI":"10.1128\/MCB.17.3.1535"},{"key":"54","unstructured":"54 Zheng B, Fiumara P, Li Y V, Georgakis G, Snell V, <i>et al<\/i>.: MEK\/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102: 1019-1027, 2003"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Harlin H, Podack E, Boothby M, Alegre M L: TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor\/p38 mitogen-activated protein kinase-dependent mechanism. Journal of immunology 169: 2451-2459, 2002","DOI":"10.4049\/jimmunol.169.5.2451"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Lee S Y, Park C G, Choi Y: T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. The Journal of experimental medicine 183: 669-674, 1996","DOI":"10.1084\/jem.183.2.669"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Telford W G, Nam S Y, Podack E R, Miller R A: CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cellular immunology 182: 125-136, 1997","DOI":"10.1006\/cimm.1997.1228"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Dai Z, Nasr I W, Reel M, Deng S, Diggs L, <i>et al<\/i>.: Impaired recall of CD8 memory T cells in immunologically privileged tissue. Journal of immunology 174: 1165-1170, 2005","DOI":"10.4049\/jimmunol.174.3.1165"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Chiarle R, Podda A, Prolla G, Podack E R, Thorbecke G J, <i>et al<\/i>.: CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. Journal of immunology 163: 194-205, 1999","DOI":"10.4049\/jimmunol.163.1.194"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Smith C A, Gruss H J, Davis T, Anderson D, Farrah T, <i>et al<\/i>.: CD30 antigen, a marker for Hodgkin\u2019s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73: 1349-1360, 1993","DOI":"10.1016\/0092-8674(93)90361-S"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Hubinger G, Muller E, Scheffrahn I, Schneider C, Hildt E, <i>et al<\/i>.: CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1\/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 20: 590-598, 2001","DOI":"10.1038\/sj.onc.1204128"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Mir S S, Richter B W, Duckett C S: Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96: 4307-4312, 2000","DOI":"10.1182\/blood.V96.13.4307.h8004307_4307_4312"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Wright C W, Rumble J M, Duckett C S: CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem 282: 10252-10262, 2007","DOI":"10.1074\/jbc.M608817200"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Krysov S V, Rowley T F, Al-Shamkhani A: Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells. <i>Mol Cancer<\/i> Ther 6: 703-711, 2007","DOI":"10.1158\/1535-7163.MCT-06-0544"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, <i>et al<\/i>.: Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14: 439-449, 1997","DOI":"10.1038\/sj.onc.1200849"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Beckmann G, Bork P: An adhesive domain detected in functionally diverse receptors. Trends in biochemical sciences 18: 40-41, 1993","DOI":"10.1016\/0968-0004(93)90049-S"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Daly N L, Scanlon M J, Djordjevic J T, Kroon P A, Smith R: Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. Proceedings of the National Academy of Sciences of the United States of America 92: 6334-6338, 1995","DOI":"10.1073\/pnas.92.14.6334"},{"key":"68","unstructured":"68 Pittaluga S, Wlodarska I, Pulford K, Campo E, Morris S W, <i>et al<\/i>.: The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23\/ALK rearrangements. Am J Pathol 151: 343-351, 1997"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8: 11-23, 2008","DOI":"10.1038\/nrc2291"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Yan B, Kuick C H, Lim M, Venkataraman K, Tennakoon C, <i>et al<\/i>.: Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. PLoS One 9: e106575, 2014","DOI":"10.1371\/journal.pone.0106575"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Pearson J D, Lee J K, Bacani J T, Lai R, Ingham R J: NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases. J Signal Transduct 2012: 123253, 2012","DOI":"10.1155\/2012\/123253"},{"key":"72","unstructured":"72 Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, <i>et al<\/i>.: Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9: 1567-1574, 1994"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Morris S W, Kirstein M N, Valentine M B, Dittmer K G, Shapiro D N, <i>et al<\/i>.: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science 263: 1281-1284, 1994","DOI":"10.1126\/science.8122112"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Hernandez L, Pinyol M, Hernandez S, Bea S, Pulford K, <i>et al<\/i>.: TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94: 3265-3268, 1999","DOI":"10.1182\/blood.V94.9.3265"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B: A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93: 3088-3095, 1999","DOI":"10.1182\/blood.V93.9.3088.409k30_3088_3095"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Meech S J, McGavran L, Odom L F, Liang X, Meltesen L, <i>et al<\/i>.: Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion. Blood 98: 1209-1216, 2001","DOI":"10.1182\/blood.V98.4.1209"},{"key":"77","unstructured":"77 Colleoni G W, Bridge J A, Garicochea B, Liu J, Filippa D A, <i>et al<\/i>.: ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 156: 781-789, 2000"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, <i>et al<\/i>.: Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 34: 354-362, 2002","DOI":"10.1002\/gcc.10033"},{"key":"79","unstructured":"79 Touriol C, Greenland C, Lamant L, Pulford K, Bernard F, <i>et al<\/i>.: Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95: 3204-3207, 2000"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Tort F, Pinyol M, Pulford K, Roncador G, Hernandez L, <i>et al<\/i>.: Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 81: 419-426, 2001","DOI":"10.1038\/labinvest.3780249"},{"key":"81","unstructured":"81 Lamant L, Gascoyne R D, Duplantier M M, Armstrong F, Raghab A, <i>et al<\/i>.: Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 37: 427-432, 2003"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Feldman A L, Vasmatzis G, Asmann Y W, Davila J, Middha S, <i>et al<\/i>.: Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. Genes Chromosomes Cancer 52: 1097-1102, 2013","DOI":"10.1002\/gcc.22104"},{"key":"83","unstructured":"83 Gascoyne R D, Lamant L, Martin-Subero J I, Lestou V S, Harris N L, <i>et al<\/i>.: ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 102: 2568-2573, 2003"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Van Roosbroeck K, Cools J, Dierickx D, Thomas J, Vandenberghe P, <i>et al<\/i>.: ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 95: 509-513, 2010","DOI":"10.3324\/haematol.2009.014761"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Takeuchi K, Soda M, Togashi Y, Ota Y, Sekiguchi Y, <i>et al<\/i>.: Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 96: 464-467, 2011","DOI":"10.3324\/haematol.2010.033514"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Lee S E, Kang S Y, Takeuchi K, Ko Y H: Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma. Hematol Oncol 32: 221-224, 2014","DOI":"10.1002\/hon.2125"},{"key":"87","unstructured":"87 Chan J K, Lamant L, Algar E, Delsol G, Tsang W Y, <i>et al<\/i>.: ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood 112: 2965-2968, 2008"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Maesako Y, Izumi K, Okamori S, Takeoka K, Kishimori C, <i>et al<\/i>.: inv(2)(p23q13)\/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman. Int J Hematol 99: 202-207, 2014","DOI":"10.1007\/s12185-013-1482-x"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Lawrence B, Perez-Atayde A, Hibbard M K, Rubin B P, Dal Cin P, <i>et al<\/i>.: TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 157: 377-384, 2000","DOI":"10.1016\/S0002-9440(10)64550-6"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Bridge J A, Kanamori M, Ma Z, Pickering D, Hill D A, <i>et al<\/i>.: Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 159: 411-415, 2001","DOI":"10.1016\/S0002-9440(10)61711-7"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Debelenko L V, Arthur D C, Pack S D, Helman L J, Schrump D S, <i>et al<\/i>.: Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 83: 1255-1265, 2003","DOI":"10.1097\/01.LAB.0000088856.49388.EA"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Debiec-Rychter M, Marynen P, Hagemeijer A, Pauwels P: ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 38: 187-190, 2003","DOI":"10.1002\/gcc.10267"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Ma Z, Hill D A, Collins M H, Morris S W, Sumegi J, <i>et al<\/i>.: Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37: 98-105, 2003","DOI":"10.1002\/gcc.10177"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 Panagopoulos I, Nilsson T, Domanski H A, Isaksson M, Lindblom P, <i>et al<\/i>.: Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. International journal of cancer 118: 1181-1186, 2006","DOI":"10.1002\/ijc.21490"},{"key":"95","unstructured":"95 Takeuchi K, Soda M, Togashi Y, Sugawara E, Hatano S, <i>et al<\/i>.: Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin Cancer Res 17: 3341-3348, 2011"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Lovly C M, Gupta A, Lipson D, Otto G, Brennan T, <i>et al<\/i>.: Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 4: 889-895, 2014","DOI":"10.1158\/2159-8290.CD-14-0377"},{"key":"97","unstructured":"97 Lee J C, Li C F, Huang H Y, Zhu M J, Marino-Enriquez A, <i>et al<\/i>.: ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol 241: 316-323, 2017"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Panagopoulos I, Gorunova L, Lund-Iversen M, Lobmaier I, Bjerkehagen B, <i>et al<\/i>.: Recurrent fusion of the genes FN1 and ALK in gastrointestinal leiomyomas. Mod Pathol 29: 1415-1423, 2016","DOI":"10.1038\/modpathol.2016.129"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Soda M, Choi Y L, Enomoto M, Takada S, Yamashita Y, <i>et al<\/i>.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007","DOI":"10.1038\/nature05945"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Rikova K, Guo A, Zeng Q, Possemato A, Yu J, <i>et al<\/i>.: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203, 2007","DOI":"10.1016\/j.cell.2007.11.025"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101 Takeuchi K, Choi Y L, Togashi Y, Soda M, Hatano S, <i>et al<\/i>.: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143-3149, 2009","DOI":"10.1158\/1078-0432.CCR-08-3248"},{"key":"102","unstructured":"102 Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, <i>et al<\/i>.: KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 7: e31323, 2012"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103 Jung Y, Kim P, Jung Y, Keum J, Kim S N, <i>et al<\/i>.: Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 51: 590-597, 2012","DOI":"10.1002\/gcc.21945"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104 Majewski I J, Mittempergher L, Davidson N M, Bosma A, Willems S M, <i>et al<\/i>.: Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 230: 270-276, 2013","DOI":"10.1002\/path.4209"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105 Hong M, Kim R N, Song J Y, Choi S J, Oh E, <i>et al<\/i>.: HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 9: 419-422, 2014","DOI":"10.1097\/JTO.0000000000000061"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106 Choi Y L, Lira M E, Hong M, Kim R N, Choi SJ, <i>et al<\/i>.: A novel fusion of TPR and ALK in lung adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 9: 563-566, 2014","DOI":"10.1097\/JTO.0000000000000093"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107 Iyevleva A G, Raskin G A, Tiurin V I, Sokolenko A P, Mitiushkina N V, <i>et al<\/i>.: Novel ALK fusion partners in lung cancer. Cancer Lett 362: 116-121, 2015","DOI":"10.1016\/j.canlet.2015.03.028"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108 Kim R N, Choi Y L, Lee M S, Lira M E, Mao M, <i>et al<\/i>.: SEC31A-ALK Fusion Gene in Lung Adenocarcinoma. Cancer research and treatment : official journal of Korean Cancer Association 48: 398-402, 2016","DOI":"10.4143\/crt.2014.254"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109 Tan D S -W, Kim D -W, Thomas M, Pantano S, Wang Y, <i>et al<\/i>.: Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1. J Clin Oncol 34: (suppl; abstr 9064), 2016","DOI":"10.1200\/JCO.2016.34.15_suppl.9064"},{"key":"110","unstructured":"110 Debelenko L V, Raimondi S C, Daw N, Shivakumar B R, Huang D, <i>et al<\/i>.: Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 24: 430-442, 2011"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111 Marino-Enriquez A, Ou W B, Weldon C B, Fletcher J A, Perez-Atayde A R: ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 50: 146-153, 2011","DOI":"10.1002\/gcc.20839"},{"key":"112","unstructured":"112 Sugawara E, Togashi Y, Kuroda N, Sakata S, Hatano S, <i>et al<\/i>.: Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 118: 4427-4436, 2012"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113 Kusano H, Togashi Y, Akiba J, Moriya F, Baba K, <i>et al<\/i>.: Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene. The American journal of surgical pathology 40: 761-769, 2016","DOI":"10.1097\/PAS.0000000000000610"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114 Lin E, Li L, Guan Y, Soriano R, Rivers C S, <i>et al<\/i>.: Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7: 1466-1476, 2009","DOI":"10.1158\/1541-7786.MCR-08-0522"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115 Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, <i>et al<\/i>.: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18: 382-384, 2012","DOI":"10.1038\/nm.2673"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116 Stransky N, Cerami E, Schalm S, Kim J L, Lengauer C: The landscape of kinase fusions in cancer. Nature communications 5: 4846, 2014","DOI":"10.1038\/ncomms5846"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117 Lee J, Kim H C, Hong J Y, Wang K, Kim S Y, <i>et al<\/i>.: Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget 6: 24320-24332, 2015","DOI":"10.18632\/oncotarget.4462"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118 Yakirevich E, Resnick M B, Mangray S, Wheeler M, Jackson C L, <i>et al<\/i>.: Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. Clin Cancer <i>Res<\/i> 22: 3831-3840, 2016","DOI":"10.1158\/1078-0432.CCR-15-3000"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119 Ren H, Tan Z P, Zhu X, Crosby K, Haack H, <i>et al<\/i>.: Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer Res 72: 3312-3323, 2012","DOI":"10.1158\/0008-5472.CAN-11-3931"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120 Kelly L M, Barila G, Liu P, Evdokimova V N, Trivedi S, <i>et al<\/i>.: Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America 111: 4233-4238, 2014","DOI":"10.1073\/pnas.1321937111"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121 McFadden D G, Dias-Santagata D, Sadow P M, Lynch K D, Lubitz C, <i>et al<\/i>.: Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. The Journal of clinical endocrinology and metabolism 99: E2457-2462, 2014","DOI":"10.1210\/jc.2014-2611"},{"key":"122","unstructured":"122 Cancer Genome Atlas Research N: Integrated genomic characterization of papillary thyroid carcinoma. Cell 159: 676-690, 2014"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123 Ji J H, Oh Y L, Hong M, Yun J W, Lee H W, <i>et al<\/i>.: Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. PLoS genetics 11: e1005467, 2015","DOI":"10.1371\/journal.pgen.1005467"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124 Perot G, Soubeyran I, Ribeiro A, Bonhomme B, Savagner F, <i>et al<\/i>.: Identification of a recurrent STRN\/ALK fusion in thyroid carcinomas. PLoS One 9: e87170, 2014","DOI":"10.1371\/journal.pone.0087170"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125 Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, <i>et al<\/i>.: Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nature communications 5: 3116, 2014","DOI":"10.1038\/ncomms4116"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126 Yeh I, de la Fouchardiere A, Pissaloux D, Mully T W, Garrido M C, <i>et al<\/i>.: Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. The American journal of surgical pathology 39: 581-591, 2015","DOI":"10.1097\/PAS.0000000000000387"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127 Grisendi S, Mecucci C, Falini B, Pandolfi P P: Nucleophosmin and cancer. Nat Rev Cancer 6: 493-505, 2006","DOI":"10.1038\/nrc1885"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128 Tort F, Campo E, Pohlman B, Hsi E: Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Hum Pathol 35: 1038-1041, 2004","DOI":"10.1016\/j.humpath.2004.05.006"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129 Martelli M P, Sozzi G, Hernandez L, Pettirossi V, Navarro A, <i>et al<\/i>.: EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174: 661-670, 2009","DOI":"10.2353\/ajpath.2009.080755"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130 Takeuchi K: Interpretation of anti-ALK immunohistochemistry results. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 8: e67-68, 2013","DOI":"10.1097\/JTO.0b013e318293e1ff"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131 Takamochi K, Takeuchi K, Hayashi T, Oh S, Suzuki K: A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. PLoS One 8: e69794, 2013","DOI":"10.1371\/journal.pone.0069794"},{"key":"132","unstructured":"132 Corao D A, Biegel J A, Coffin C M, Barr FG, Wainwright L M, <i>et al<\/i>.: ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatr Dev Pathol 12: 275-283, 2009"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133 Foss H D, Anagnostopoulos I, Araujo I, Assaf C, Demel G, <i>et al<\/i>.: Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 88: 4005-4011, 1996","DOI":"10.1182\/blood.V88.10.4005.bloodjournal88104005"},{"key":"134","unstructured":"134 Herbst H, Tippelmann G, Anagnostopoulos I, Gerdes J, Schwarting R, <i>et al<\/i>.: Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin\u2019s disease and Ki-1-positive anaplastic large cell lymphoma: dissociation between phenotype and genotype. Leuk Res 13: 103-116, 1989"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135 O\u2019Connor N T, Stein H, Gatter K C, Wainscoat J S, Crick J, <i>et al<\/i>.: Genotypic analysis of large cell lymphomas which express the Ki-1 antigen. Histopathology 11: 733-740, 1987","DOI":"10.1111\/j.1365-2559.1987.tb02687.x"},{"key":"136","unstructured":"136 Krenacs L, Wellmann A, Sorbara L, Himmelmann A W, Bagdi E, <i>et al<\/i>.: Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin\u2019s disease: evidence for distinct cellular origin. Blood 89: 980-989, 1997"},{"key":"137","unstructured":"137 Delsol G, Al Saati T, Gatter K C, Gerdes J, Schwarting R, <i>et al<\/i>.: Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 130: 59-70, 1988"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138 Rosso R, Paulli M, Magrini U, Kindl S, Boveri E, <i>et al<\/i>.: Anaplastic large cell lymphoma, CD30\/Ki-1 positive, expressing the CD15\/Leu-M1 antigen. Immunohistochemical and morphological relationships to Hodgkin\u2019s disease. Virchows Arch A Pathol Anat Histopathol 416: 229-235, 1990","DOI":"10.1007\/BF01678982"},{"key":"139","unstructured":"139 Falini B, Flenghi L, Pileri S, Gambacorta M, Bigerna B, <i>et al<\/i>.: PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am J Pathol 142: 1359-1372, 1993"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140 Feldman A L, Law M E, Inwards D J, Dogan A, McClure R F, <i>et al<\/i>.: PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. Mod Pathol 23: 593-602, 2010","DOI":"10.1038\/modpathol.2010.4"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141 Bonzheim I, Geissinger E, Roth S, Zettl A, Marx A, <i>et al<\/i>.: Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 104: 3358-3360, 2004","DOI":"10.1182\/blood-2004-03-1037"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142 Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, <i>et al<\/i>.: NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res 69: 8611-8619, 2009","DOI":"10.1158\/0008-5472.CAN-09-2655"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143 Hassler M R, Pulverer W, Lakshminarasimhan R, Redl E, Hacker J, <i>et al<\/i>.: Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling. Cell Rep 17: 596-608, 2016","DOI":"10.1016\/j.celrep.2016.09.018"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144 Lamant L, de Reynies A, Duplantier M M, Rickman D S, Sabourdy F, <i>et al<\/i>.: Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109: 2156-2164, 2007","DOI":"10.1182\/blood-2006-06-028969"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145 Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, <i>et al<\/i>.: Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood 125: 124-132, 2015","DOI":"10.1182\/blood-2014-08-594507"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146 Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, <i>et al<\/i>.: Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 140: 516-526, 2008","DOI":"10.1111\/j.1365-2141.2007.06924.x"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147 Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, <i>et al<\/i>.: Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27: 516-532, 2015","DOI":"10.1016\/j.ccell.2015.03.006"},{"key":"148","unstructured":"148 Abate F, Zairis S, Ficarra E, Acquaviva A, Wiggins C H, <i>et al<\/i>.: Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer. BMC Syst Biol 8: 97, 2014"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149 Mereu E, Pellegrino E, Scarfo I, Inghirami G, Piva R: The heterogeneous landscape of ALK negative ALCL. Oncotarget 2017","DOI":"10.18632\/oncotarget.14503"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150 Parrilla Castellar E R, Jaffe E S, Said J W, Swerdlow S H, Ketterling R P, <i>et al<\/i>.: ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124: 1473-1480, 2014","DOI":"10.1182\/blood-2014-04-571091"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151 Scarfo I, Pellegrino E, Mereu E, Kwee I, Agnelli L, <i>et al<\/i>.: Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood 127: 221-232, 2016","DOI":"10.1182\/blood-2014-12-614503"},{"key":"152","unstructured":"152 Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, <i>et al<\/i>.: Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM\/ALK: a distinct clinicopathologic entity. Blood 86: 1954-1960, 1995"},{"key":"153","unstructured":"153 Escalon M P, Liu N S, Yang Y, Hess M, Walker P L, <i>et al<\/i>.: Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103: 2091-2098, 2005"},{"key":"154","unstructured":"154 Falini B, Pulford K, Pucciarini A, Carbone A, De Wolf-Peeters, C, <i>et al<\/i>.: Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 94: 3509-3515, 1999"},{"key":"155","doi-asserted-by":"crossref","unstructured":"155 Liang X, Branchford B, Greffe B, McGavran L, Carstens B, <i>et al<\/i>.: Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma. J Pediatr Hematol Oncol 35: e209-213, 2013","DOI":"10.1097\/MPH.0b013e3182815046"},{"key":"156","unstructured":"156 Moritake H, Shimonodan H, Marutsuka K, Kamimura S, Kojima H, <i>et al<\/i>.: C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17\/C-MYC. Am J Hematol 86: 75-78, 2011"},{"key":"157","doi-asserted-by":"crossref","unstructured":"157 Zinzani P L, Pileri S, Bendandi M, Buzzi M, Sabattini E, <i>et al<\/i>.: Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 16: 1532-1537, 1998","DOI":"10.1200\/JCO.1998.16.4.1532"},{"key":"158","doi-asserted-by":"crossref","unstructured":"158 Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, <i>et al<\/i>.: Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia 27: 416-422, 2013","DOI":"10.1038\/leu.2012.205"},{"key":"159","doi-asserted-by":"crossref","unstructured":"159 Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, <i>et al<\/i>.: Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood 123: 334-337, 2014","DOI":"10.1182\/blood-2013-09-526202"},{"key":"160","doi-asserted-by":"crossref","unstructured":"160 Damm-Welk C, Busch K, Burkhardt B, Schieferstein J, Viehmann S, <i>et al<\/i>.: Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood 110: 670-677, 2007","DOI":"10.1182\/blood-2007-02-066852"},{"key":"161","unstructured":"161 Le Deley M C, Reiter A, Williams D, Delsol G, Oschlies I, <i>et al<\/i>.: Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood 111: 1560-1566, 2008"},{"key":"162","unstructured":"162 Williams D M, Hobson R, Imeson J, Gerrard M, McCarthy K, <i>et al<\/i>.: Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children\u2019s Cancer Study Group chemotherapy regimens. Br J Haematol 117: 812-820, 2002"},{"key":"163","unstructured":"163 Brugieres L, Le Deley M C, Rosolen A, Williams D, Horibe K, <i>et al.<\/i>: Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 27: 897-903, 2009"},{"key":"164","unstructured":"164 Le Deley M C, Rosolen A, Williams D M , Horibe K, Wrobel G, <i>et al.<\/i>: Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 28: 3987-3993, 2010"},{"key":"165","unstructured":"165 Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch, I, <i>et al<\/i>.: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 97: 3699-3706, 2001"},{"key":"166","unstructured":"166 Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmermann M, <i>et al<\/i>.: Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 12: 899-908, 1994"},{"key":"167","doi-asserted-by":"crossref","unstructured":"167 Zhang X M, Li Y X, Wang W H, Jin J, Wang S L, <i>et al<\/i>.: Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma. Eur J Haematol 90: 195-201, 2013","DOI":"10.1111\/ejh.12060"},{"key":"168","doi-asserted-by":"crossref","unstructured":"168 Briski R, Feldman A L, Bailey N G, Lim M S, Ristow K, <i>et al<\/i>.: Survival in patients with limited-stage peripheral T-cell lymphomas. Leuk Lymphoma 56: 1665-1670, 2015","DOI":"10.3109\/10428194.2014.963078"},{"key":"169","unstructured":"169 Abramson J S, Feldman T, Kroll-Desrosiers A R, Muffly L S, Winer E, <i>et al<\/i>.: Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25: 2211-2217, 2014"},{"key":"170","doi-asserted-by":"crossref","unstructured":"170 Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, <i>et al<\/i>.: Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 151: 159-166, 2010","DOI":"10.1111\/j.1365-2141.2010.08329.x"},{"key":"171","unstructured":"171 d\u2019Amore F, Relander T, Lauritzsen G F, Jantunen E, Hagberg H, <i>et al<\/i>.: Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30: 3093-3099, 2012"},{"key":"172","unstructured":"172 Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, <i>et al<\/i>.: High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20: 1977-1984, 2009"},{"key":"173","doi-asserted-by":"crossref","unstructured":"173 Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, <i>et al<\/i>.: Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 28: 1885-1891, 2014","DOI":"10.1038\/leu.2014.79"},{"key":"174","doi-asserted-by":"crossref","unstructured":"174 Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, <i>et al<\/i>.: Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20: 1533-1538, 2006","DOI":"10.1038\/sj.leu.2404306"},{"key":"175","unstructured":"175 Deconinck E, Lamy T, Foussard C, Gaillard F, Delwail V, <i>et al<\/i>.: Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 109: 736-742, 2000"},{"key":"176","doi-asserted-by":"crossref","unstructured":"176 Gkotzamanidou M, Papadimitriou C A: Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Crit Rev Oncol Hematol 89: 248-261, 2014","DOI":"10.1016\/j.critrevonc.2013.08.016"},{"key":"177","doi-asserted-by":"crossref","unstructured":"177 Yared J, Kimball A: The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev 39: 51-59, 2013","DOI":"10.1016\/j.ctrv.2012.03.011"},{"key":"178","doi-asserted-by":"crossref","unstructured":"178 Song K W, Mollee P, Keating A, Crump M: Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 120: 978-985, 2003","DOI":"10.1046\/j.1365-2141.2003.04203.x"},{"key":"179","doi-asserted-by":"crossref","unstructured":"179 Jagasia M, Morgan D, Goodman S, Hamilton K, Kinney M, <i>et al<\/i>.: Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 45: 2261-2267, 2004","DOI":"10.1080\/10428190412331272749"},{"key":"180","doi-asserted-by":"crossref","unstructured":"180 Smith S M, Burns L J, van Besien K, Lerademacher J, He W, <i>et al<\/i>.: Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31: 3100-3109, 2013","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"181","unstructured":"181 Le Gouill S, Milpied N, Buzyn A, De Latour R P, Vernant J P, <i>et al<\/i>.: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26: 2264-2271, 2008"},{"key":"182","doi-asserted-by":"crossref","unstructured":"182 Deng C, Pan B, O\u2019Connor O A: Brentuximab vedotin. Clin Cancer Res 19: 22-27, 2013","DOI":"10.1158\/1078-0432.CCR-12-0290"},{"key":"183","doi-asserted-by":"crossref","unstructured":"183 Doronina S O, Toki B E, Torgov M Y, Mendelsohn B A, Cerveny C G, <i>et al<\/i>.: Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21: 778-784, 2003","DOI":"10.1038\/nbt832"},{"key":"184","doi-asserted-by":"crossref","unstructured":"184 Sutherland M S, Sanderson R J, Gordon K A, Andreyka J, Cerveny C G, <i>et al<\/i>.: Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281: 10540-10547, 2006","DOI":"10.1074\/jbc.M510026200"},{"key":"185","doi-asserted-by":"crossref","unstructured":"185 Okeley N M, Miyamoto J B, Zhang X, Sanderson R J, Benjamin D R, <i>et al<\/i>.: Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16: 888-897, 2010","DOI":"10.1158\/1078-0432.CCR-09-2069"},{"key":"186","doi-asserted-by":"crossref","unstructured":"186 Francisco J A, Cerveny C G, Meyer D L, Mixan B J, Klussman K, <i>et al<\/i>.: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102: 1458-1465, 2003","DOI":"10.1182\/blood-2003-01-0039"},{"key":"187","doi-asserted-by":"crossref","unstructured":"187 Younes A, Bartlett N L, Leonard J P, Kennedy D A, Lynch C M, <i>et al<\/i>.: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363: 1812-1821, 2010","DOI":"10.1056\/NEJMoa1002965"},{"key":"188","doi-asserted-by":"crossref","unstructured":"188 Fanale M A, Forero-Torres A, Rosenblatt J D, Advani R H, Franklin A R, <i>et al<\/i>.: A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies. Clin Cancer Res 18: 248-255, 2012","DOI":"10.1158\/1078-0432.CCR-11-1425"},{"key":"189","unstructured":"189 Pro B, Advani R, Brice P, Bartlett N L, Rosenblatt J D, <i>et al<\/i>.: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30: 2190-2196, 2012"},{"key":"190","doi-asserted-by":"crossref","unstructured":"190 Pro B, Advani R H, Brice P, Bartlett N L, Rosenblatt J D, <i>et al<\/i>.: Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood 128: 4144-4144, 2016","DOI":"10.1182\/blood.V128.22.4144.4144"},{"key":"191","doi-asserted-by":"crossref","unstructured":"191 Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, <i>et al<\/i>.: Phase I \/ II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci 105: 840-846, 2014","DOI":"10.1111\/cas.12435"},{"key":"192","doi-asserted-by":"crossref","unstructured":"192 Bartlett N L, Chen R, Fanale M A, Brice P, Gopal A, <i>et al<\/i>.: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7: 24, 2014","DOI":"10.1186\/1756-8722-7-24"},{"key":"193","doi-asserted-by":"crossref","unstructured":"193 Katayama R, Lovly C, Shaw A T: Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 21: 2227-2235, 2015","DOI":"10.1158\/1078-0432.CCR-14-2791"},{"key":"194","unstructured":"194 Kwak E L, Bang Y J, Camidge D R, Shaw A T, Solomon B, <i>et al<\/i>.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703, 2010"},{"key":"195","doi-asserted-by":"crossref","unstructured":"195 Galkin A V, Melnick J S, Kim S, Hood T L, Li N, <i>et al<\/i>.: Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the United States of America 104: 270-275, 2007","DOI":"10.1073\/pnas.0609412103"},{"key":"196","doi-asserted-by":"crossref","unstructured":"196 Wan W, Albom M S, Lu L, Quail M R, Becknell N C, <i>et al<\/i>.: Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 107: 1617-1623, 2006","DOI":"10.1182\/blood-2005-08-3254"},{"key":"197","doi-asserted-by":"crossref","unstructured":"197 Piva R, Chiarle R, Manazza A D, Taulli R, Simmons W, <i>et al<\/i>.: Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 107: 689-697, 2006","DOI":"10.1182\/blood-2005-05-2125"},{"key":"198","doi-asserted-by":"crossref","unstructured":"198 Christensen J G, Zou H Y, Arango M E, Li Q, Lee J H, <i>et al<\/i>.: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6: 3314-3322, 2007","DOI":"10.1158\/1535-7163.MCT-07-0365"},{"key":"199","doi-asserted-by":"crossref","unstructured":"199 Gambacorti-Passerini C, Messa C, Pogliani E M: Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364: 775-776, 2011","DOI":"10.1056\/NEJMc1013224"},{"key":"200","doi-asserted-by":"crossref","unstructured":"200 Ordemann R, Stohlmacher J, Beuthien-Baumann B, Platzek I, van den Hoff J, <i>et al<\/i>.: Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Ann Hematol 92: 125-127, 2013","DOI":"10.1007\/s00277-012-1524-0"},{"key":"201","doi-asserted-by":"crossref","unstructured":"201 Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, <i>et al<\/i>.: Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst 106: djt378, 2014","DOI":"10.1093\/jnci\/djt378"},{"key":"202","doi-asserted-by":"crossref","unstructured":"202 Cleary J M, Rodig S, Barr P M, Shinagare A B, Clark J W, <i>et al<\/i>.: Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma. J Natl Compr Canc Netw 12: 323-326; quiz 326, 2014","DOI":"10.6004\/jnccn.2014.0034"},{"key":"203","unstructured":"203 Conyers R, Rao A, Solomon B, Seymour J F: Editor in Chief: Response to Eyre et al. \u201cALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease\u201d. Eur J Haematol 94: 86-87, 2015"},{"key":"204","doi-asserted-by":"crossref","unstructured":"204 Kothari S, Ud-Din N, Lisi M, Coyle T: Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report. J Med Case Rep 10: 176, 2016","DOI":"10.1186\/s13256-016-0963-y"},{"key":"205","doi-asserted-by":"crossref","unstructured":"205 Lawrence K, Berry B, Handshoe J, Hout D, Mazzola R, <i>et al<\/i>.: Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease. BMC Res Notes 8: 308, 2015","DOI":"10.1186\/s13104-015-1277-7"},{"key":"206","doi-asserted-by":"crossref","unstructured":"206 Mahuad C V, Reparaz Mde L, Zerga M E, Aizpurua M F, Casali C, <i>et al<\/i>.: Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib. Rare Tumors 8: 6266, 2016","DOI":"10.4081\/rt.2016.6266"},{"key":"207","unstructured":"207 Mosse Y P, Lim M S, Voss S D, Wilner K, Ruffner K, <i>et al<\/i>.: Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study. Lancet Oncol 14: 472-480, 2013"},{"key":"208","doi-asserted-by":"crossref","unstructured":"208 Gambacorti-Passerini C, Horibe K, Braiteh F, Huang H -q, Shi Y, <i>et al<\/i>.: Safety and Clinical Activity Of Crizotinib In Patients With ALK-Rearranged Hematologic Malignancies. Blood 122: 4342, 2013","DOI":"10.1182\/blood.V122.21.4342.4342"},{"key":"209","doi-asserted-by":"crossref","unstructured":"209 Gambacorti-Passerini C, Mussolin L, Brugieres L: Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. N Engl J Med 374: 95-96, 2016","DOI":"10.1056\/NEJMc1511045"},{"key":"210","doi-asserted-by":"crossref","unstructured":"210 Marsilje T H, Pei W, Chen B, Lu W, Uno T, <i>et al<\/i>.: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl) phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 56: 5675-5690, 2013","DOI":"10.1021\/jm400402q"},{"key":"211","doi-asserted-by":"crossref","unstructured":"211 Shaw A T, Kim D W, Mehra R, Tan D S, Felip E, <i>et al<\/i>.: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370: 1189-1197, 2014","DOI":"10.1056\/NEJMoa1311107"},{"key":"212","doi-asserted-by":"crossref","unstructured":"212 Richly H, Kim T M, Schuler M, Kim D W, Harrison S J, <i>et al<\/i>.: Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. Blood 126: 1257-1258, 2015","DOI":"10.1182\/blood-2014-12-617779"},{"key":"213","unstructured":"213 Minard-Colin V, Brugieres L, Reiter A, Cairo M S, Gross T G, <i>et al<\/i>.: Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J Clin Oncol 33: 2963-2974, 2015"},{"key":"214","doi-asserted-by":"crossref","unstructured":"214 Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H: Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 351: 215-221, 2014","DOI":"10.1016\/j.canlet.2014.05.020"},{"key":"215","unstructured":"215 Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, <i>et al<\/i>.: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1\u20132 study. The Lancet Oncology 14: 590-598, 2013"},{"key":"216","unstructured":"216 Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, <i>et al<\/i>.: Prospective and clinical validation of ALK immunohistochemistry: results from the phase I\/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol 27: 185-192, 2016"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/57\/3\/57_17023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T06:53:56Z","timestamp":1693378436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/57\/3\/57_17023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":216,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.17023","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}